Daniel G. Welch - 15 May 2026 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Reporting relationship: Director
Issuer ticker: PRTA
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 May 2026, 21:29:00 UTC
Prior SEC filing: 18 May 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael J. Malecek, as Attorney-in-Fact for Daniel G. Welch

Key filing fact

Daniel G. Welch filed Form 4 for PROTHENA CORP PUBLIC LTD CO (PRTA) on 15 May 2026.

Key facts

This page summarizes Daniel G. Welch's Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 May 2026, 21:29.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001206199 Primary reporting owner

WELCH DANIEL G

Relationship: Director
Address: C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE
Signature: /s/ Michael J. Malecek, as Attorney-in-Fact for Daniel G. Welch
Signature date: 15 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRTA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +27,000
Change %
Price: $0.000000^*
Shares after: 27,000
Date: 15 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 27,000
Exercise price: $9.76
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.